HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFF Swings Open Door On Growing Probiotic Sales After Closing Merger With DuPont Nutrition

Executive Summary

Two weeks after merging with probiotic ingredient leader DuPont Nutrition & Biosciences, International Flavors & Fragrances hosts first of two online conferences to help manufacturers and marketers “unlock the power of the microbiome wellness industry." 

You may also be interested in...



IFF’s ‘Differentiating’ R&D This Year Includes Probiotics, Biodegradable Fragrance; Q1 Sales Increase 13%

New York firm International Flavors & Fragrances Inc. aims to stand out in 2022 with an R&D pipeline that includes probiotics, plant-based protein and biodegradable fragrances, says CEO Frank Clyburn, speaking in his first quarterly earnings presentation since taking the helm in February.

DuPont’s Nutrition Business Spin-Off Through Subsidiaries Merger With IFF Moves Toward Closing

IFF announces preliminary results of more than 99% of votes approving issuing shares pursuant to an agreement that positions it as acquiring DuPont Nutrition & Biosciences under a “reverse Morris trust” transaction. The merger is between DuPont Nutrition & Biosciences and a subsidiary IFF established as a corporate entity to conduct the transaction.

Proposed Rule Making More OTC Switches Likely In US Makes More Tools Necessary For Sponsors

OTC drug development and marketing consultants spoke with HBW Insight about FDA’s “Nonprescription Drug Product with an Additional Condition for Nonprescription Use” proposed rule. In first of two articles, they discuss proposed rule’s likely impacts on industry and remaining concerns around incorporating extra-label information in drug labeling.

Topics

Latest News
UsernamePublicRestriction

Register

RS151016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel